Compare PCB & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCB | ARMP |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | 61 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.0M | 295.5M |
| IPO Year | 2018 | 1996 |
| Metric | PCB | ARMP |
|---|---|---|
| Price | $23.38 | $8.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $25.50 | $15.00 |
| AVG Volume (30 Days) | 17.9K | ★ 73.3K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 48.28 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $2,899,000.00 | N/A |
| Revenue This Year | $13.73 | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $31.65 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $19.28 | $1.74 |
| 52 Week High | $25.15 | $14.98 |
| Indicator | PCB | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 37.96 |
| Support Level | $21.12 | $7.43 |
| Resistance Level | $24.25 | $12.11 |
| Average True Range (ATR) | 0.50 | 1.32 |
| MACD | -0.17 | -0.23 |
| Stochastic Oscillator | 7.85 | 11.97 |
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.